338 related articles for article (PubMed ID: 24708522)
1. Slit2N and Robo4 regulate lymphangiogenesis through the VEGF-C/VEGFR-3 pathway.
Yu J; Zhang X; Kuzontkoski PM; Jiang S; Zhu W; Li DY; Groopman JE
Cell Commun Signal; 2014 Apr; 12():25. PubMed ID: 24708522
[TBL] [Abstract][Full Text] [Related]
2. Roundabout4 suppresses glioma-induced endothelial cell proliferation, migration and tube formation in vitro by inhibiting VEGR2-mediated PI3K/AKT and FAK signaling pathways.
Cai H; Xue Y; Li Z; Hu Y; Wang Z; Liu W; Li Z; Liu Y
Cell Physiol Biochem; 2015; 35(5):1689-705. PubMed ID: 25833462
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.
Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F
Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor receptor-3 directly interacts with phosphatidylinositol 3-kinase to regulate lymphangiogenesis.
Coso S; Zeng Y; Opeskin K; Williams ED
PLoS One; 2012; 7(6):e39558. PubMed ID: 22745786
[TBL] [Abstract][Full Text] [Related]
5. Qingjie Fuzheng Granule suppresses lymphangiogenesis in colorectal cancer via the VEGF-C/VEGFR-3 dependent PI3K/AKT pathway.
Huang B; Lu Y; Gui M; Guan J; Lin M; Zhao J; Mao Q; Lin J
Biomed Pharmacother; 2021 May; 137():111331. PubMed ID: 33578235
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor-C secreted by pancreatic cancer cell line promotes lymphatic endothelial cell migration in an in vitro model of tumor lymphangiogenesis.
Ochi N; Matsuo Y; Sawai H; Yasuda A; Takahashi H; Sato M; Funahashi H; Okada Y; Manabe T
Pancreas; 2007 May; 34(4):444-51. PubMed ID: 17446844
[TBL] [Abstract][Full Text] [Related]
7. The β
Kumaravel S; Abbey CA; Bayless KJ; Chakraborty S
Am J Physiol Cell Physiol; 2020 Dec; 319(6):C1045-C1058. PubMed ID: 33052069
[TBL] [Abstract][Full Text] [Related]
8. uPARAP/Endo180 receptor is a gatekeeper of VEGFR-2/VEGFR-3 heterodimerisation during pathological lymphangiogenesis.
Durré T; Morfoisse F; Erpicum C; Ebroin M; Blacher S; García-Caballero M; Deroanne C; Louis T; Balsat C; Van de Velde M; Kaijalainen S; Kridelka F; Engelholm L; Struman I; Alitalo K; Behrendt N; Paupert J; Noel A
Nat Commun; 2018 Dec; 9(1):5178. PubMed ID: 30518756
[TBL] [Abstract][Full Text] [Related]
9. Suppression of lymphangiogenesis in human lymphatic endothelial cells by simultaneously blocking VEGF-C and VEGF-D/VEGFR-3 with norcantharidin.
Liu ZY; Qiu HO; Yuan XJ; Ni YY; Sun JJ; Jing W; Fan YZ
Int J Oncol; 2012 Nov; 41(5):1762-72. PubMed ID: 22922710
[TBL] [Abstract][Full Text] [Related]
10. Molecular controls of lymphatic VEGFR3 signaling.
Deng Y; Zhang X; Simons M
Arterioscler Thromb Vasc Biol; 2015 Feb; 35(2):421-9. PubMed ID: 25524775
[TBL] [Abstract][Full Text] [Related]
11. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis.
Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K
Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522
[TBL] [Abstract][Full Text] [Related]
12. Tumour necrosis factor superfamily member 15 (Tnfsf15) facilitates lymphangiogenesis via up-regulation of Vegfr3 gene expression in lymphatic endothelial cells.
Qin TT; Xu GC; Qi JW; Yang GL; Zhang K; Liu HL; Xu LX; Xiang R; Xiao G; Cao H; Wei Y; Zhang QZ; Li LY
J Pathol; 2015 Nov; 237(3):307-18. PubMed ID: 26096340
[TBL] [Abstract][Full Text] [Related]
13. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling.
Chen HM; Tsai CH; Hung WC
Oncotarget; 2015 Jun; 6(17):14940-52. PubMed ID: 25909285
[TBL] [Abstract][Full Text] [Related]
14. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D.
Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG
J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial-specific molecule-1 as a novel mediator of lymphangiogenesis.
Shin JW; Huggenberger R; Detmar M
Blood; 2008 Sep; 112(6):2318-26. PubMed ID: 18614759
[TBL] [Abstract][Full Text] [Related]
16. Total saponins of panaxnotoginseng promotes lymphangiogenesis by activation VEGF-C expression of lymphatic endothelial cells.
Li J; Chen Y; Zhang L; Xing L; Xu H; Wang Y; Shi Q; Liang Q
J Ethnopharmacol; 2016 Dec; 193():293-302. PubMed ID: 27553977
[TBL] [Abstract][Full Text] [Related]
17. Doxycycline inhibits inflammation-induced lymphangiogenesis in mouse cornea by multiple mechanisms.
Han L; Su W; Huang J; Zhou J; Qiu S; Liang D
PLoS One; 2014; 9(9):e108931. PubMed ID: 25268699
[TBL] [Abstract][Full Text] [Related]
18. Semaphorin 4D expression is associated with a poor clinical outcome in cervical cancer patients.
Liu H; Yang Y; Xiao J; Yang S; Liu Y; Kang W; Li X; Zhang F
Microvasc Res; 2014 May; 93():1-8. PubMed ID: 24603190
[TBL] [Abstract][Full Text] [Related]
19. Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-kappaB and Prox1.
Flister MJ; Wilber A; Hall KL; Iwata C; Miyazono K; Nisato RE; Pepper MS; Zawieja DC; Ran S
Blood; 2010 Jan; 115(2):418-29. PubMed ID: 19901262
[TBL] [Abstract][Full Text] [Related]
20. CD34+ VEGFR-3+ progenitor cells have a potential to differentiate towards lymphatic endothelial cells.
Tan YZ; Wang HJ; Zhang MH; Quan Z; Li T; He QZ
J Cell Mol Med; 2014 Mar; 18(3):422-33. PubMed ID: 24450475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
